Yoshio Ishizaka Net Worth

The estimated Net Worth of Yoshio Ishizaka is at least $19.6 Tysiąc dollars as of 21 August 2017. Yoshio Ishizaka owns over 5,000 units of Medicinova Inc stock worth over $19,600 and over the last 11 years Yoshio sold MNOV stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Yoshio Ishizaka MNOV stock SEC Form 4 insiders trading

Yoshio has made over 3 trades of the Medicinova Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Yoshio bought 5,000 units of MNOV stock worth $25,850 on 21 August 2017.

The largest trade Yoshio's ever made was buying 5,000 units of Medicinova Inc stock on 21 August 2017 worth over $25,850. On average, Yoshio trades about 1,667 units every 112 days since 2014. As of 21 August 2017 Yoshio still owns at least 10,000 units of Medicinova Inc stock.

You can see the complete history of Yoshio Ishizaka stock trades at the bottom of the page.

What's Yoshio Ishizaka's mailing address?

Yoshio's mailing address filed with the SEC is C/O MEDICINOVA, INC., 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA, CA, 92037.

Insiders trading at Medicinova Inc

Over the last 18 years, insiders at Medicinova Inc have traded over $200,908 worth of Medicinova Inc stock and bought 459,744 units worth $1,581,779 . The most active insiders traders include Jeff Himawan, Masatsune Okajima oraz Yuichi Iwaki. On average, Medicinova Inc executives and independent directors trade stock every 95 days with the average trade being worth of $74,094. The most recent stock trade was executed by Hideki Nagao on 28 November 2022, trading 6,754 units of MNOV stock currently worth $15,197.

What does Medicinova Inc do?

pharmaceutical preparations

Complete history of Yoshio Ishizaka stock trades at Medicinova Inc

Medicinova Inc executives and stock owners

Medicinova Inc executives and other stock owners filed with the SEC include:

• Yuichi Iwaki,
  President, Chief Executive Officer, Director
• Kazuko Matsuda,
  Chief Medical Officer, Director
• Geoffrey O'brien,
  Vice President
• Dr. Yuichi Iwaki M.D., Ph.D.,
  Co-Founder, Pres, CEO & Exec. Director
• Dr. Kazuko Matsuda M.D., M.P.H., MPH, Ph.D.,
  Chief Medical Officer & Director
• Hideki Nagao,
  Independent Director
• Carolyn Beaver,
  Director
• Edward Stepanow,
  Chief Financial Officer
• Jeffrey Himawan,
  Independent Chairman of the Board
• John O'Neil CPA,
  Controller
• Dr. David H. Crean Ph.D.,
  Chief Bus. Officer
• Dr. Federico Gaeta Ph.D.,
  Chief Scientific Officer
• Douglas G Paulin CPA, CPA,
  Chief Financial Officer
• Yutaka Kobayashi,
  Director
• Yoshio Ishizaka,
  Director
• Masatsune Okajima,
  VP and Head of Japanese Office
• Federico C.A. Gaeta,
  Chief Scientific Officer
• Tatsuo Izumi,
  Director
• Den Boom Esther Van,
  Chief Financial Officer
• Jeff Himawan,
  Director
• John K A Prendergast,
  Director
• Hiroaki Shigeta,
  Director
• Kirk William Johnson,
  Chief Scientific Officer
• Arlene Morris,
  Director
• Michael Denis Coffee,
  Chief Business Officer
• David D O'toole,
  Director
• Alan W Dunton,
  Director
• Shintaro Asako,
  VP and Chief Financial Officer
• Richard E Sr Gammans,
  Chief Development Officer
• Daniel Vapnek,
  Director
• Kenneth W Locke,
  Chief Scientific Officer
• Michael E Kalafer,
  Chief Medical Officer
• Nicole Lemerond,
  Director